MTCM
BMRN icon

Mint Tower Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mint Tower Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,700
Closed -$1.42M – 302
2022
Q4 		$1.42M Sell
13,700
-2,300
-14% -$216K 0.13% 148
2022
Q3 		$1.36M Buy
+16,000
New +$1.42M 0.11% 207

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mint Tower Capital Management's BMRN Position: Q1 2023 in Review

Mint Tower Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 13,700 shares — an estimated $1.42M sold.

Mint Tower Capital Management first reported a position in BMRN in Q3 2022 and held it in 2 quarters. The position peaked at $1.42M in Q4 2022. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

  • Mint Tower Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Mint Tower Capital Management sold 13,700 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $1.42M.
  • Mint Tower Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Mint Tower Capital Management's BioMarin Pharmaceuticals position peaked at $1.42M in Q4 2022.
  • 552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on Mint Tower Capital Management's 13F filing for Q1 2023, filed 9 May 2023.